Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines DOI Creative Commons
Aziz Alami Chentoufi,

Jeffrey B. Ulmer,

Lbachir BenMohamed

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 13(1), P. 30 - 30

Published: Dec. 31, 2024

The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is in its sixth year and being maintained inability of current spike-alone-based vaccines to prevent transmission leading continuous emergence variants sub-variants concern (VOCs). This underscores critical need for next-generation broad-spectrum pan-Coronavirus (pan-CoV vaccine) break this cycle end pandemic. development a pan-CoV vaccine offering protection against wide array VOCs requires two key elements: (1) identifying protective antigens that are highly conserved between passed, current, future VOCs; (2) developing safe efficient antigen delivery system induction broad-based long-lasting B- T-cell immunity. review will present state platforms involving multifaceted approach, including bioinformatics, molecular structural biology, immunology, advanced computational methods; discuss challenges facing effective platforms; (3) highlight potential nucleoside-modified mRNA encapsulated lipid nanoparticles (LNP) as platform well suited needs vaccine, such ability induce immunity amenable large-scale manufacturing safely provide durable threats.

Language: Английский

SARS-CoV-2 BA.2.86 is susceptible to the neutralizing antibody MO11 targeting subdomain 1 despite the E554K mutation near the epitope DOI Creative Commons

Natsumi Hasegawa,

Mitsuhiro Nishimura,

Rei Takamiya

et al.

Journal of Virology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

Citations

0
An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants DOI Creative Commons

L Rojas,

Rocío Alejandra Ruiz‐Manzano,

Miguel Andrés Velasco-Elizondo

et al.

Pathogens, Journal Year: 2024, Volume and Issue: 13(12), P. 1081 - 1081

Published: Dec. 9, 2024

SARS-CoV-2 (Betacoronavirus pandemicum) is responsible for the disease identified by World Health Organization (WHO) as COVID-19. We designed “CHIVAX 2.1”, a multi-epitope vaccine, containing ten immunogenic peptides with conserved B-cell and T-cell epitopes in receceptor binding domain (RBD) sequences of different variants concern (VoCs). evaluated immune response mice immunized 20 or 60 µg chimeric protein two alum adjuvants (Alhydrogel® Adju-Phos®), plus PHAD®, two-immunization regimen (0 21 days). Serum samples were collected on days 0, 21, 31, 72 post first immunization, antibody titers determined indirect ELISA, while lymphoproliferation assays cytokine production flow cytometry. The presence neutralizing antibodies was assessed surrogate neutralization assays. Higher total IgG, IgG1, IgG2a antibodies, well increased proliferation rates specific CD4+ CD8+ T cells, observed μg Adju-Phos®/PHAD®. This formulation also generated highest levels TNF-α IFN-γ, addition to against Delta Omicron VoC. These findings indicate potential this vaccine combined promising platform viral infections, eliciting TH1 TH1:TH2 balanced cell response.

Language: Английский

Citations

0
Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines DOI Creative Commons
Aziz Alami Chentoufi,

Jeffrey B. Ulmer,

Lbachir BenMohamed

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 13(1), P. 30 - 30

Published: Dec. 31, 2024

The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is in its sixth year and being maintained inability of current spike-alone-based vaccines to prevent transmission leading continuous emergence variants sub-variants concern (VOCs). This underscores critical need for next-generation broad-spectrum pan-Coronavirus (pan-CoV vaccine) break this cycle end pandemic. development a pan-CoV vaccine offering protection against wide array VOCs requires two key elements: (1) identifying protective antigens that are highly conserved between passed, current, future VOCs; (2) developing safe efficient antigen delivery system induction broad-based long-lasting B- T-cell immunity. review will present state platforms involving multifaceted approach, including bioinformatics, molecular structural biology, immunology, advanced computational methods; discuss challenges facing effective platforms; (3) highlight potential nucleoside-modified mRNA encapsulated lipid nanoparticles (LNP) as platform well suited needs vaccine, such ability induce immunity amenable large-scale manufacturing safely provide durable threats.

Language: Английский

Citations

0